Assenagon Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Assenagon Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,825,678	Closed	-$79.5M	–	1516
2023 Q3	$79.5M	Buy	1,825,678 +1,016,858	+126%	+$36.3M	0.25%	67
2023 Q2	$29.2M	Buy	808,820 +552,860	+216%	+$22.8M	0.1%	166
2023 Q1	$9.52M	Buy	255,960 +86,175	+51%	+$3.88M	0.03%	398
2022 Q4	$7.69M	Sell	169,785 -23,643	-12%	-$1.53M	0.03%	436
2022 Q3	$13.5M	Sell	193,428 -658,522	-77%	-$48.7M	0.05%	290
2022 Q2	$57.2M	Buy	851,950 +798,528	+1,495%	+$50.8M	0.21%	99
2022 Q1	$4.39M	Sell	53,422 -38,738	-42%	-$3.96M	0.01%	558
2021 Q4	$13.5M	Sell	92,160 -270,440	-75%	-$42M	0.04%	263
2021 Q3	$64.1M	Sell	362,600 -959	-0.3%	-$154K	0.21%	92
2021 Q2	$58.7M	Buy	363,559 +72,021	+25%	+$11.6M	0.2%	95
2021 Q1	$49.9M	Buy	291,538 +245,488	+533%	+$48.6M	0.2%	89
2020 Q4	$10.1M	Sell	46,050 -82,750	-64%	-$17.9M	0.04%	247
2020 Q3	$21.4M	Buy	128,800 +27,426	+27%	+$3.75M	0.12%	121
2020 Q2	$11.6M	Buy	+101,374	New	+$9.83M	0.07%	165

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Assenagon Asset Management's MRTX Position: Q4 2023 in Review

Assenagon Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 1,825,678 shares — an estimated $79.5M sold.

Assenagon Asset Management first reported a position in MRTX in Q2 2020 and held it in 14 quarters. The position peaked at $79.5M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Assenagon Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Assenagon Asset Management sold 1,825,678 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $79.5M.
Assenagon Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 14 quarters.
Assenagon Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $79.5M in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Assenagon Asset Management's 13F filing for Q4 2023, filed 17 Jan 2024.